Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645069 · ClinicalTrials.gov registry record · Phase 1
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Adagene.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT04645069: Completed Phase 1 study, sponsored by Adagene.
NCT04645069 is a Phase 1 study that has completed, run by Adagene. The registered enrollment target is 58 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04645069, a Phase 1 study, has completed, sponsored by Adagene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
Interventions
- BIOLOGICAL ADG126 Mono
- BIOLOGICAL ADG126-anti PD1
- BIOLOGICAL ADG126-ADG106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 1 |
What the finished NCT04645069 record still lists
NCT04645069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which ADG126 Mono is the first listed.
NCT04645069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04645069 about?
NCT04645069 is a clinical study titled "ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors". ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
What is the current status of trial NCT04645069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2021-03-15. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT04645069?
The interventions under investigation include: ADG126 Mono (BIOLOGICAL), ADG126-anti PD1 (BIOLOGICAL), ADG126-ADG106 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04645069?
This trial is sponsored by Adagene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04645069's enrollment target sits among peer trials
58 895th of 2000 higher than 1,100 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI